AR099510A1 - Régimen de dosaje del compuesto fgf-18 - Google Patents
Régimen de dosaje del compuesto fgf-18Info
- Publication number
- AR099510A1 AR099510A1 ARP150100508A ARP150100508A AR099510A1 AR 099510 A1 AR099510 A1 AR 099510A1 AR P150100508 A ARP150100508 A AR P150100508A AR P150100508 A ARP150100508 A AR P150100508A AR 099510 A1 AR099510 A1 AR 099510A1
- Authority
- AR
- Argentina
- Prior art keywords
- fgf
- compound
- use according
- mcg
- administered
- Prior art date
Links
- 102000003977 fibroblast growth factor 18 Human genes 0.000 title abstract 12
- 108090000370 fibroblast growth factor 18 Proteins 0.000 title abstract 12
- 239000002131 composite material Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 10
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 210000001188 articular cartilage Anatomy 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 208000015100 cartilage disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14000600 | 2014-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099510A1 true AR099510A1 (es) | 2016-07-27 |
Family
ID=50151088
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100508A AR099510A1 (es) | 2014-02-20 | 2015-02-20 | Régimen de dosaje del compuesto fgf-18 |
| ARP150100507A AR099558A1 (es) | 2014-02-20 | 2015-02-20 | Régimen de dosaje del compuesto fgf-18 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100507A AR099558A1 (es) | 2014-02-20 | 2015-02-20 | Régimen de dosaje del compuesto fgf-18 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9889179B2 (Direct) |
| EP (2) | EP3119417B1 (Direct) |
| JP (2) | JP6431083B2 (Direct) |
| KR (2) | KR102410986B1 (Direct) |
| CN (2) | CN106232622A (Direct) |
| AR (2) | AR099510A1 (Direct) |
| AU (2) | AU2015220777B2 (Direct) |
| BR (2) | BR112016018685A2 (Direct) |
| CA (2) | CA2938791A1 (Direct) |
| DK (2) | DK3107559T3 (Direct) |
| ES (2) | ES2688551T3 (Direct) |
| HR (2) | HRP20181570T1 (Direct) |
| HU (1) | HUE040350T2 (Direct) |
| IL (2) | IL247084B (Direct) |
| LT (2) | LT3107559T (Direct) |
| MX (2) | MX2016010872A (Direct) |
| NZ (1) | NZ723148A (Direct) |
| PL (2) | PL3107559T3 (Direct) |
| PT (2) | PT3107559T (Direct) |
| RS (2) | RS57853B1 (Direct) |
| RU (2) | RU2691946C2 (Direct) |
| SG (2) | SG11201606502YA (Direct) |
| SI (2) | SI3107559T1 (Direct) |
| WO (2) | WO2015124727A1 (Direct) |
| ZA (2) | ZA201605547B (Direct) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10086112B2 (en) | 2014-02-20 | 2018-10-02 | Merck Patent Gmbh | Implant comprising FGF-18 |
| CA2938791A1 (en) | 2014-02-20 | 2015-08-27 | Merck Patent Gmbh | Fgf-18 compound dosing regimen |
| AU2016211950A1 (en) | 2015-01-29 | 2017-07-13 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| RU2743075C2 (ru) | 2016-02-22 | 2021-02-15 | Новартис Аг | Способы применения агонистов fxr |
| HUE058786T2 (hu) | 2017-09-29 | 2022-09-28 | Merck Patent Gmbh | FGF-18 vegyületre vonatkozó válaszkészség elõrejelzésére szolgáló metabolikus biomarkerek |
| DK3688468T3 (da) | 2017-09-29 | 2022-06-20 | Merck Patent Gmbh | Inflammatoriske biomarkører til forudsigelse af modtageligheden for fgf-18 forbindelse |
| IL281333B2 (en) | 2018-09-10 | 2025-11-01 | Merck Patent Gmbh | A method for reducing risk in a clinical trial |
| CA3127729A1 (en) * | 2019-02-08 | 2020-08-13 | Merck Patent Gmbh | Treatment of patients at risk of rapid progression of osteoarthritis |
| WO2025077768A1 (en) * | 2023-10-11 | 2025-04-17 | Sichuan Real & Best Biotech Co., Ltd. | Compositions and methods for treating arthritis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003279835B2 (en) * | 2002-10-07 | 2009-09-10 | Zymogenetics, Inc. | Methods of administering FGF18 |
| US20060009389A1 (en) * | 2004-07-06 | 2006-01-12 | Moore Emma E | Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use |
| US20070243132A1 (en) * | 2005-12-22 | 2007-10-18 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
| KR101419961B1 (ko) * | 2006-08-25 | 2014-07-30 | 아레스 트레이딩 에스.에이. | Ｆｇｆ-18 로 연골 질환의 치료 |
| CN101505787B (zh) * | 2006-08-25 | 2013-09-04 | 阿雷斯贸易股份有限公司 | 软骨障碍的治疗 |
| DE102006043260A1 (de) * | 2006-09-11 | 2008-03-27 | Krones Ag | Etikettieranlage |
| CA2830882C (en) * | 2011-03-22 | 2021-03-16 | Dinesh Barawkar | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| EP3107591B1 (en) | 2014-02-20 | 2018-04-18 | Merck Patent GmbH | Fgf-18 in graft transplantation and tissue engineering procedures |
| US10086112B2 (en) | 2014-02-20 | 2018-10-02 | Merck Patent Gmbh | Implant comprising FGF-18 |
| CA2938791A1 (en) | 2014-02-20 | 2015-08-27 | Merck Patent Gmbh | Fgf-18 compound dosing regimen |
-
2015
- 2015-02-20 CA CA2938791A patent/CA2938791A1/en not_active Abandoned
- 2015-02-20 HR HRP20181570TT patent/HRP20181570T1/hr unknown
- 2015-02-20 LT LTEP15706006.2T patent/LT3107559T/lt unknown
- 2015-02-20 CA CA2938793A patent/CA2938793A1/en active Pending
- 2015-02-20 SG SG11201606502YA patent/SG11201606502YA/en unknown
- 2015-02-20 PL PL15706006T patent/PL3107559T3/pl unknown
- 2015-02-20 CN CN201580020536.2A patent/CN106232622A/zh active Pending
- 2015-02-20 BR BR112016018685A patent/BR112016018685A2/pt not_active Application Discontinuation
- 2015-02-20 DK DK15706006.2T patent/DK3107559T3/en active
- 2015-02-20 JP JP2016553329A patent/JP6431083B2/ja active Active
- 2015-02-20 LT LTEP15707076.4T patent/LT3119417T/lt unknown
- 2015-02-20 ES ES15707076.4T patent/ES2688551T3/es active Active
- 2015-02-20 MX MX2016010872A patent/MX2016010872A/es active IP Right Grant
- 2015-02-20 HR HRP20181572TT patent/HRP20181572T1/hr unknown
- 2015-02-20 AU AU2015220777A patent/AU2015220777B2/en active Active
- 2015-02-20 AU AU2015220773A patent/AU2015220773B2/en active Active
- 2015-02-20 SG SG11201606505UA patent/SG11201606505UA/en unknown
- 2015-02-20 CN CN201580020532.4A patent/CN106456713A/zh active Pending
- 2015-02-20 ES ES15706006.2T patent/ES2689071T3/es active Active
- 2015-02-20 SI SI201530428T patent/SI3107559T1/sl unknown
- 2015-02-20 JP JP2016553284A patent/JP6431082B2/ja active Active
- 2015-02-20 AR ARP150100508A patent/AR099510A1/es unknown
- 2015-02-20 DK DK15707076.4T patent/DK3119417T3/en active
- 2015-02-20 SI SI201530410T patent/SI3119417T1/sl unknown
- 2015-02-20 HU HUE15706006A patent/HUE040350T2/hu unknown
- 2015-02-20 AR ARP150100507A patent/AR099558A1/es unknown
- 2015-02-20 EP EP15707076.4A patent/EP3119417B1/en active Active
- 2015-02-20 PL PL15707076T patent/PL3119417T3/pl unknown
- 2015-02-20 BR BR112016018696A patent/BR112016018696A2/pt not_active Application Discontinuation
- 2015-02-20 PT PT15706006T patent/PT3107559T/pt unknown
- 2015-02-20 WO PCT/EP2015/053624 patent/WO2015124727A1/en not_active Ceased
- 2015-02-20 NZ NZ723148A patent/NZ723148A/en unknown
- 2015-02-20 PT PT15707076T patent/PT3119417T/pt unknown
- 2015-02-20 MX MX2016010871A patent/MX2016010871A/es active IP Right Grant
- 2015-02-20 KR KR1020167025246A patent/KR102410986B1/ko active Active
- 2015-02-20 RS RS20181167A patent/RS57853B1/sr unknown
- 2015-02-20 RU RU2016137289A patent/RU2691946C2/ru active
- 2015-02-20 RS RS20181168A patent/RS57709B1/sr unknown
- 2015-02-20 EP EP15706006.2A patent/EP3107559B1/en active Active
- 2015-02-20 KR KR1020167025245A patent/KR102410988B1/ko active Active
- 2015-02-20 WO PCT/EP2015/053631 patent/WO2015124731A1/en not_active Ceased
- 2015-02-20 RU RU2016137292A patent/RU2700582C2/ru active
- 2015-02-20 US US15/120,131 patent/US9889179B2/en active Active
- 2015-02-20 US US15/120,134 patent/US9724388B2/en active Active
-
2016
- 2016-08-03 IL IL247084A patent/IL247084B/en active IP Right Grant
- 2016-08-03 IL IL247083A patent/IL247083B/en active IP Right Grant
- 2016-08-10 ZA ZA2016/05547A patent/ZA201605547B/en unknown
- 2016-08-10 ZA ZA2016/05548A patent/ZA201605548B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099510A1 (es) | Régimen de dosaje del compuesto fgf-18 | |
| AR131056A2 (es) | Composiciones para tratar un trastorno hipofosfatémico | |
| MX2019012884A (es) | Terapia de combinacion. | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| JP2015517488A5 (Direct) | ||
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX388482B (es) | Métodos para tratar el virus de la hepatitis c. | |
| MX2015012538A (es) | Combinacion de dos agentes entivirales para el tratamiento de hepatitis c. | |
| MX2015012536A (es) | Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| JP2017507142A5 (Direct) | ||
| JP2017512194A5 (Direct) | ||
| AR112166A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b | |
| AR116451A1 (es) | Administración oral de análogos del péptido glp-1 | |
| MX389088B (es) | Métodos para tratar el vhc. | |
| JP2017507145A5 (Direct) | ||
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| AR108790A1 (es) | Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria | |
| EA201791525A3 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
| EA201790991A1 (ru) | Способ лечения с использованием пегилированного интерферона | |
| EA201792314A1 (ru) | Фармацевтическая комбинация эверолимуса и дактолисиба |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |